Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,268,555 papers from all fields of science
Search
Sign In
Create Free Account
S 4661
Known as:
S-4661
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
doripenem
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Development of an HPLC method for the determination of doripenem in human and mouse serum.
Christina A. Sutherland
,
D. Nicolau
Journal of chromatography. B, Analytical…
2007
Corpus ID: 42289133
2006
2006
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
H. Huynh
,
D. Biedenbach
,
Ronald N. Jones
Diagnostic microbiology and infectious disease
2006
Corpus ID: 35802625
Highly Cited
2005
Highly Cited
2005
In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis
Yunhua Chen
,
E. Garber
,
+4 authors
L. Saiman
Antimicrobial Agents and Chemotherapy
2005
Corpus ID: 8755552
ABSTRACT Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant…
Expand
2005
2005
Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan
Yoshio Kobayashi
Journal of Infection and Chemotherapy
2005
Corpus ID: 13672225
S-4661 is a methylcarbapenem antibiotic newly developed in Japan. We evaluated the combined actions of carbapenems, including S…
Expand
Highly Cited
2004
Highly Cited
2004
MECHANISM OF THE DRUG INTERACTION BETWEEN VALPROIC ACID AND CARBAPENEM ANTIBIOTICS IN MONKEYS AND RATS
Y. Nakajima
,
M. Mizobuchi
,
+5 authors
Toshiro Yamaguchi
Drug Metabolism And Disposition
2004
Corpus ID: 8131376
The Ministry of Health and Welfare, Japan banned coadministration of carbapenems, such as panipenem/betamipron (PAPM), meropenem…
Expand
Review
2002
Review
2002
Recent developments in carbapenems
G. Nicoletti
,
G. Russo
,
G. Bonfiglio
Expert Opinion on Investigational Drugs
2002
Corpus ID: 44930359
Carbapenems are β-lactam antibiotics characterised by the presence of a β-lactam ring with a carbon instead of sulfone in the 4…
Expand
2000
2000
Comparative in vitro Activity of S-4661, a New Parenteral Carbapenem, and Other Antimicrobial Agents against Respiratory Pathogens
A. Watanabe
,
H. Takahashi
,
+5 authors
T. Nukiwa
Chemotherapy
2000
Corpus ID: 27353737
The activity of S-4661, a new parenteral carbapenem antibiotic, was evaluated against 202 recent clinical isolates of respiratory…
Expand
Highly Cited
1998
Highly Cited
1998
In Vitro and In Vivo Antibacterial Activities of S-4661, a New Carbapenem
M. Tsuji
,
Y. Ishii
,
A. Ohno
,
S. Miyazaki
,
K. Yamaguchi
Antimicrobial Agents and Chemotherapy
1998
Corpus ID: 23753409
ABSTRACT The in vitro and in vivo antibacterial activities of S-4661, a new 1β-methylcarbapenem, were compared with those of…
Expand
Highly Cited
1998
Highly Cited
1998
Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics.
Yoshitaka Yano
,
Takayoshi Oguma
,
Hiroshi Nagata
,
Shimaru Sasaki
Journal of Pharmacy and Science
1998
Corpus ID: 38030884
A new pharmacodynamic model for the analysis of in vitro bactericidal kinetics was developed based on the logistic growth model…
Expand
Highly Cited
1996
Highly Cited
1996
A novel 1 beta-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 beta-methylcarbapenems.
Y. Iso
,
T. Irie
,
Y. Nishino
,
K. Motokawa
,
Y. Nishitani
Journal of antibiotics (Tokyo. )
1996
Corpus ID: 19535438
The synthesis and biological activity of (1R,5S,6S)-2-[(3S,5S)-5-substituted pyrrolidin-3-ylthio]-6-[(1R)-1-hydroxyethyl]-1…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE